GB2343376B - Stable apomorphine solution formulations - Google Patents

Stable apomorphine solution formulations

Info

Publication number
GB2343376B
GB2343376B GB9925602A GB9925602A GB2343376B GB 2343376 B GB2343376 B GB 2343376B GB 9925602 A GB9925602 A GB 9925602A GB 9925602 A GB9925602 A GB 9925602A GB 2343376 B GB2343376 B GB 2343376B
Authority
GB
United Kingdom
Prior art keywords
stable
solution formulations
apomorphine solution
apomorphine
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9925602A
Other versions
GB2343376A (en
GB9925602D0 (en
Inventor
Eva Bernini
Gaetano Brambilla
Paolo Chiesi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of GB9925602D0 publication Critical patent/GB9925602D0/en
Publication of GB2343376A publication Critical patent/GB2343376A/en
Application granted granted Critical
Publication of GB2343376B publication Critical patent/GB2343376B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB9925602A 1998-10-30 1999-10-28 Stable apomorphine solution formulations Expired - Fee Related GB2343376B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002331A IT1303684B1 (en) 1998-10-30 1998-10-30 FORMULATIONS OF APOMORPHINE IN SOLUTION STABLE OVER TIME.

Publications (3)

Publication Number Publication Date
GB9925602D0 GB9925602D0 (en) 1999-12-29
GB2343376A GB2343376A (en) 2000-05-10
GB2343376B true GB2343376B (en) 2003-12-31

Family

ID=11380970

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9925602A Expired - Fee Related GB2343376B (en) 1998-10-30 1999-10-28 Stable apomorphine solution formulations

Country Status (6)

Country Link
BR (1) BR9905305A (en)
ES (1) ES2156763B1 (en)
FR (1) FR2785188B1 (en)
GB (1) GB2343376B (en)
GR (1) GR990100373A (en)
IT (1) IT1303684B1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770376B2 (en) * 1999-09-29 2004-02-19 Procter & Gamble Company, The Compositions having improved stability
TW200526268A (en) * 2003-12-17 2005-08-16 Takeda Pharmaceutical Injectable composition
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
CN104349768B (en) 2012-06-05 2017-11-07 纽罗德姆有限公司 Composition comprising apomorphine and organic acid and application thereof
WO2015157212A1 (en) * 2014-04-10 2015-10-15 Us Worldmeds, Llc Stable apomorphine composition and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAPLUS abstract accession number 1970:428848 *
CAPLUS abstract accession number 1980:591977 *
CAPLUS abstract accession number 1985:119532 *

Also Published As

Publication number Publication date
FR2785188A1 (en) 2000-05-05
ES2156763A1 (en) 2001-07-01
ES2156763B1 (en) 2002-03-01
FR2785188B1 (en) 2004-10-29
IT1303684B1 (en) 2001-02-23
BR9905305A (en) 2001-03-20
ITMI982331A1 (en) 2000-04-30
GB2343376A (en) 2000-05-10
GR990100373A (en) 2000-06-30
GB9925602D0 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
PL343021A1 (en) Formulations
PL341372A1 (en) Cellecoxibe containing compositions
EP1016400A4 (en) Composition for external use
PL347102A1 (en) Thermally stable polyetheramines
PL338186A1 (en) Beneficial agent compositions containing alpha-hydroxyesters
EP0976407A4 (en) Antiseptic composition
GB2334721B (en) Cleansing composition
GB9812119D0 (en) Composition
GB9806788D0 (en) Composition
GB9806793D0 (en) Composition
GB2343376B (en) Stable apomorphine solution formulations
GB9806312D0 (en) Novel formulations
GB2331703B (en) Disinfectant compositions
GB9813714D0 (en) Composition
GB9810180D0 (en) Novel formulation
GB9815001D0 (en) Formulations
GB9815002D0 (en) Formulations
GB9804041D0 (en) Composition
GB9816697D0 (en) Liquid formulations
GB9810181D0 (en) Novel formulations
GB2333938B (en) Improvements to cultivator
GB9904033D0 (en) Improvements to bowsers
GB9803982D0 (en) Composition
GB9800011D0 (en) Composition
GB9813572D0 (en) Solution

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20111028